GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Phase IV obligations for its Commit nicotine polacrilex lozenge include a study of consumers who are contraindicated for use of the OTC smoking cessation drug due to underlying health conditions, FDA's Oct. 31 approval letter states